Taysha Gene Therapies updates to Rett program TSHA-102
Taysha Gene Therapies has announced several updates to the TSHA-102 program through a press release today on International Rare Disease Day.
This includes an expansion of the adult study from Canada to the USA which means that an arm of the trial in patients age 12 and over can now start in the USA.
Taysha has also announced that they have been approved by the study’s Independent Data Monitoring Committee (IDMC) to move to the next dose level, a higher dose of TSHA-102. This patient is expected to be dosed in the 2nd quarter of 2024.
The Independent Data Monitoring Committee has also approved dosing of the second child in the first group in the US children’s trial. This patient is expected to be dosed in the first quarter of 2024.
Read Taysha’s full press release here
Read Taysha’s letter to Community Leaders below.
Scroll down for our key takeaways.
Key takeaways
- Taysha’s adult study (12+) expanding from Canada to USA.
- Ongoing adult study in Canada now proceeding to a higher dose after clearance from IDMC.
- Ongoing children’s study in USA approved to move to 2nd patient (low dose).
For more information about Taysha Gene Therapies ongoing clinical trials, please watch the Reverse Rett Taysha Gene Therapies Emerging Therapies Bitesize session from 18 January 2024.